CPT code 81210 represents the technical laboratory assay to detect common mutations in the BRAF gene, a key molecular test in oncology for tumor profiling and therapeutic decision‑making. Nationally, BRAF testing informs targeted therapy choices and diagnostic classification across multiple cancer types, making the code central to cancer molecular diagnostics infrastructure. The analysis covers major national payers and Medicare, reflecting common coverage drivers and billing practices for molecular pathology services. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical sites of service, and the clinical context for BRAF testing. The publication summarizes payer coverage themes, common billing modifiers and claim components, and how CPT code 81210 is positioned relative to laboratory technical components in reimbursement workflows. Where available, benchmarking and claim line considerations are outlined to aid coding and billing teams, alongside policy and documentation factors that affect medical necessity determinations. Data not available in the input is noted where applicable.